At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 28 enrolled
Drug / intervention
Zostavax +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™
In Brief
A Phase 4 clinical trial evaluating Zostavax and Placebo for Herpes Zoster and Fibrosis. Completed, enrolled 28 participants.
Detailed Summary
Study Design: Double-blinded, placebo controlled study of the efficacy of Zostavax in cirrhosis. Subjects will receive either Zostavax or placebo and will be followed for four months. Hypothesis: The investigators hypothesize Zostavax would induce cell-based immunity in cirrhotic patients like that seen in elderly patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster, Fibrosis
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJun 2013
Primary CompletionJul 2015
First PostedNov 2016
TodayJul 2026
First PostedNov 8, 2016
Enrollment StartJun 1, 2013
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 9.7 years ago
Interventions
Zostavaxbiological
Vaccination with one dose of Zostavax per Zostavax package insert
Placeboother
Injection of 0.65 mL of sterile normal saline